WebAs the Venture Leader for Centyrex, a Johnson & Johnson Venture, Karyn focused on designer protein platform technologies. She is co-inventor on the Centyrin patents and has led the team advancing the Centyrin platform since its inception. WebDr. LaPlaca earned her undergraduate degree in Biomedical Engineering from The Catholic University of America, Washington, DC, in 1991 and her M.S.E. (1992) and Ph.D. (1996) …
Life Science Start-Up Aro Biotherapeutics Expands at Pennovation …
WebGreater Philadelphia Area Research Scientist at Centyrex Biotechnology Education California Polytechnic State University-San Luis Obispo 1991 — 1994 BS, Biology UCLA, B.S. Experience Centyrex September 2010 - Present Centyrex January 2008 - Present Centocor/Johnson & Johnson 2005 - Present Centocor R&D a Johnson & … WebMay 13, 2024 · May 13, 2024 4:33 PM PDT Aro Biotherapeutics Co. showed its muscle-targeted Centyrin-GYS1 siRNA conjugate, ABX1100, reduced toxic accumulation of muscle glycogen in a mouse model of Pompe disease. lamodula betten
Donna Klein - Scientific Director - RNA and Targeted ... - LinkedIn
WebAs the Venture Leader for Centyrex, a Johnson & Johnson Venture, Karyn focused on designer protein platform technologies. She is co-inventor on the Centyrin patents and … WebKaryn O’Neil has more than 30 years of experience in peptide, antibody and protein engineering. As the Venture Leader for Centyrex, a Johnson & Johnson Venture, Karyn focused on designer protein platform technologies. She is co-inventor on the Centyrin patents and has led the team advancing the Centyrin platform since its inception. She … WebFeb 21, 2024 · The company’s president and CEO is Sue Dillon, an R&D champion and the ex-global therapeutic area head for immunology in the … jesi affitti vacanze